Compound library
Understand what people are taking.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Blue-green microalgae (Arthrospira) consumed as a dried whole-food powder; its phycocyanin and protein content have been studied in human trials for effects on blood lipids, glycated haemoglobin and immune markers.
9 of 13 results reported a benefit, from 3 published studies.
3 randomised trials, 169 people
Side effects: measured in 2 results. 1 result reported more side effects than the comparison group.
These are the figures the studies reported, not a prediction for any one person. Where several studies measured the same thing in the same unit, we show a simple average and say so. Every individual result is listed below.
See every resultFrequent illness, weak immune response, slow recovery from infections.
Also known as: Arthrospira platensis, Arthrospira maxima
Every published result for this pair, extracted and audited.
These charts group published studies by what they reported and how they were run — green marks studies that reported a benefit for this pairing. Tiers run from pooled analyses of many trials (strongest) to one-off observational reports.
Direction of reported outcomes for Spirulina in immune support.
Study designs behind these findings.
Hand-selected PubMed studies, linked to the originals.
Ordered by strength of evidence, then result direction.
01Comparison of adjuvant and neoadjuvant therapies for muscle invasive bladder cancer: A network meta-analysisPetrelli F, et al. · Urologic oncology · 2026PMID 40935764 ↗02Clinical benefits and risks of high-dose intravenous vitamin C: a systematic reviewAlangari A, et al. · Journal of medicine and life · 2026PMID 41815850 ↗03Surviving Sepsis Campaign International Guidelines for the Management of Sepsis and Septic Shock in Children 2026Weiss SL, et al. · Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2026PMID 41869844 ↗04Surviving Sepsis Campaign International Guidelines for the Management of Sepsis and Septic Shock in Children 2026Weiss SL, et al. · Intensive care medicine · 2026PMID 41870559 ↗Be the first to share what you noticed with Spirulina for immune support. Why counts start empty.
Every measured outcome, one row per finding - numbers exactly as reported.
| Study | Design | n | Duration | Outcome measured | Reported result | Direction |
|---|---|---|---|---|---|---|
| PMID 26195001 2015 | Randomised trial | - | 12 months | fasting blood glucose concentration | reported qualitatively | Benefit |
| PMID 26195001 2015 | Randomised trial | - | - | haemoglobin level | reported qualitatively | Benefit |
| PMID 26195001 2015 | Randomised trial | 169 | 12 months | viral load levels | 74.7×10(3)-30.87×10(3) copies/mL | Benefit |
| PMID 25057105 2014 | Randomised trial | 73 | three-month | CD4 T-cells | reported qualitatively | No benefit |
| PMID 25057105 2014 | Randomised trial | 73 | three-month | creatinine level | 0.1 g/dL (p < 0.001) | Harm / risk |
| PMID 25057105 2014 | Randomised trial | 73 | three-month | immune activation by CD8 T-cells expressing CD38 | reported qualitatively | No benefit |
| PMID 25057105 2014 | Randomised trial | 73 | three-month | total antioxidant capacity of the serum (TAOS) | 56 (1-98) µM (p < 0.001) | Benefit |
| PMID 25057105 2014 | Randomised trial | 73 | three-month | urea levels | reported qualitatively | No benefit |
| PMID 25057105 2014 | Randomised trial | 73 | three-month | viral load | reported qualitatively | No benefit |
| PMID 25057105 2014 | Randomised trial | 73 | three-month | weight increase | 0.5 kg (p < 0.05; p < 0.05) | Unclear |
| PMID 18714150 2008 | Randomised trial | 78 | 16 consecutive weeks | IL-6 concentration | reported qualitatively (p < 0.05) | Benefit |
| PMID 18714150 2008 | Randomised trial | 78 | 16 consecutive weeks | plasma cholesterol | reported qualitatively (p < 0.05) | Benefit |
| PMID 18714150 2008 | Randomised trial | 78 | 16 consecutive weeks | plasma interleukin (IL)-2 concentration | reported qualitatively (p < 0.05) | Benefit |
| PMID 18714150 2008 | Randomised trial | 78 | 16 consecutive weeks | superoxide dismutase activity | reported qualitatively (p < 0.05) | Benefit |
| PMID 18714150 2008 | Randomised trial | 78 | 16 consecutive weeks | total antioxidant status | reported qualitatively (p < 0.05) | Benefit |